As the largest health-based laboratory in the region, Northwell Health Labs provides a wide range of lab services from highly trained, compassionate experts. And we’re right where you need us in ...

The National Liver Cancer Screening Trial is an adaptive randomized phase IV Trial comparing ultrasound-based versus biomarker-based screening in 5500 patients with cirrhosis from any etiology or ...

Randomized, open-label, multicentric pivotal trial of SonoCloud-9 combined with carboplatin (CB) and nab-paclitaxel (nabPTX) vs Standard of Care (SoC) lomustine (CCNU) or temozolomide (TMZ) in ...

NISMAT is a pioneering hospital-based facility that’s solely dedicated to sports medicine. NISMAT has been at the forefront of advancing the field since our establishment in 1973 at Lenox Hill ...

We believe that athletes should have access to coordinated care to ensure their safety and well-being during practice and competition. Through our certified athletic trainer services, we provide ...

What do Northwell Health’s Sundeep Singh Boparai, DHA, MHA, Al Roker, and Patrick Dempsey have in common? They are among the 10 distinguished recipients of the 2025 Health Advocacy Awards, an honor ...

Prospective Survey Study of Bone Health and Adherence to Osteoporosis Management in Patients with Early Stage Breast Cancer on Adjuvant Endocrine Therapy with ...

This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL).

NACHO-BIO: A Translational Biology Platform to Advance Understanding of Pathogenesis and Improve Outcomes for Patients with Histiocytic Disorders ...

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial ...

The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18 years).

This phase II trial studies how stopping tyrosine kinase inhibitors will affect treatment-free remission in patients with chronic myeloid leukemia in chronic phase.